Still trying to figure out the main advantages of SM6 over some of the other antibody on the market to treat MM - e.g. Daratumumab,Tabalumab, MOR202 etc etc...
Why would Onyx choose SM6 as a potential partner over other antibodies out there or another class of MM Tx?
Can someone please elaborate?
why onyx sees the opportunity - deja vu ?, page-3
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(12.5%) |
Mkt cap ! $7.201M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $564 | 161.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 39 | 29348732 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 26555626 | 17 |
View Market Depth
| Last trade - 12.59pm 18/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |